Physician profile
Leiah Anfinson
NPI 1225097520
$1,956.96
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $74.85 · 2021: $428 · 2022: $336 · 2023: $375 · 2024: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $607.87 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Merz North America, INC. | $426.07 | 2019-2023 | Xeomin |
| Pfizer INC. | $129.85 | 2022-2024 | |
| Hikma Pharmaceuticals USA | $120.22 | 2019-2023 | Kloxxado, Mitigare, Ryaltris |
| Idorsia Pharmaceuticals US INC | $72.60 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $61.97 | 2019-2024 | Zepbound |
| Allergan, INC. | $56.96 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.62 | 2019-2024 | Austedo Xr |
| Corcept Therapeutics | $41.24 | 2023 | Korlym |
| Galderma Laboratories, L.P. | $40.57 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $36.21 | 2021 | |
| Nabriva Therapeutics, Plc | $31.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.07 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $24.03 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.84 | 2024 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.29 | 2023 | Sunosi |
| Genzyme Corporation | $20.65 | 2022 | |
| Genentech USA, INC. | $20.00 | 2021 | |
| Exact Sciences Corporation | $16.40 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.88 | 2022 | |
| Phadia US INC. | $15.84 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $15.61 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.58 | 2023 | Adthyza |
| Eisai INC. | $14.60 | 2020 | |
| Acella Pharmaceuticals, LLC | $13.34 | 2024 | NP Thyroid 60 |
| Astellas Pharma US INC | $13.16 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $13.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leiah Anfinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.